Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effectsParkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (tremor) medium term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effects Parkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects: Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects:Parkinsonism (tremor) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (> 15‐35 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes adverse effects: 1. Clinically significant extrapyramidal side… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus standard‐higher dose (greater than or equal to 6‐<10 mg/day) · patients with schizophrenia
HIGH DOSE (greater than or equal to 10 mg/day) probably leads to higher adverse effects: EPS: unspecified ‐ when compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia
RISPERIDONE may leads to higher adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term… compared with PLACEBO (low certainty).
1 finding from 1 review
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ total ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 4.67 [1.53, 14.26]
Studies not reported
Very low
Intervention not reported
Adverse effects Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement:not stated · people suffering from high altitude illness
1 finding from 1 review
Adverse effects ‐ important extrapyramidal adverse effects · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect… compared with placebo (very low certainty).
1 finding from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ purpura ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 15
Studies not reported
Very low
Adverse effects ‐ Blurred vision No of patients with blurred vision · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: blurred vision Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus verapamil versus verapamil ‐ regrowth ‐ keloid scars ‐ · participants with hypertrophic and keloid scars
It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ 595‐nm PDL plus… compared with other treatment (very low certainty).
1 finding from 1 review
RR 1.5 [0.27, 8.22]
Studies not reported
Very low
Adverse effects Local or systemic inflammatory response, cardiovascular abnormalities, and thromboembolic complications · patients with Buerger's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found